On May 16th, the 4th Asia Summit on Global Health was held at the Hong Kong Convention and Exhibition Centre, which was jointly organized by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC). During the event, The Hong Kong Polytechnic University (hereinafter called PolyU) and Pamedic Holdings (Shenzhen) Limited (hereinafter called Pamedic Holdings) held a signing ceremony, marking the official launch of their strategic cooperation in the field of nuclear medicine.
As is known, PolyU, with a long history of 86 years, is a dynamic, ambitious and forward-looking innovative world-class university with seven national laboratories and research centers, including the State Key Laboratory of Chemical Biology and Drug Discovery. PolyU leads in scientific research in the fields of nuclear medical imaging and radiological science, and has cultivated a large number of outstanding innovative talents of science and technology.
Co-founded by C Cheng Holdings Limited, Pamedic Holdings Limited (UK) and Mark Wong & Associates Limited, Pamedic Holdings (Shenzhen) Limited is an international company dedicated to the research, development and production of medical isotopes.
Pamedic Holdings is committed to building a global integration of industry, academia, research, diagnosis and treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human life and health.
As is informed, PolyU and Pamedic Holdings will further cooperate in the field of nuclear medicine around scientific research, technological innovation, talent cultivation to jointly promote the development of scientific and technological innovation for nuclear medicine.

▲Speech by Christopher Zhao, Vice President (Research and Innovation), The Hong Kong Polytechnic University
At the signing ceremony, Professor Christopher Zhao, Vice-President of PolyU, stated, "The cooperation with Pamedic Holdings marks a solid step forward in the field of scientific research and innovation. Pamedic Holdings has been committed to achieving breakthroughs in the field of nuclear medicine. With PolyU’s research strength in medical imaging and radiological sciences, it’s convinced that we can achieve mutual benefits in research cooperation, technology transfer, talent cultivation and other aspects. We are very much looking forward to working hand in hand with Pamedic Holdings to explore the cutting edge of science and technology, tackle practical problems so as to contribute to the progress of society."

▲Speech by Mr. Ivan Fu, Chairman of the Board of Directors of PanMediso Holdings
Ivan Fu, Chairman of the Board of Directors of Pamedic Holdings, stated, "We are very much looking forward to promoting the development of the medical and healthcare industries of both the Mainland China and HK through our collaboration, so as to contribute to the promotion of healthcare in the Guangdong-Hong Kong-Macao Greater Bay Area and even the whole country. We will focus on the fields of nuclear medicine imaging diagnosis and radiotherapy to jointly promote the research and development and application of innovative technologies, explore research on major topics and projects, and cultivate key talents. We strive to bring innovative power through in-depth co-operation in various aspects to further promote the development of nuclear medicine and life sciences."

▲Signing Ceremony between PolyU and Pamedic Holdings
After the signing ceremony, the representatives of Luzhou city leaders, Shenzhen Bay Laboratory and Pamedic Holdings team moved to PolyU for further discussion on cooperation in nuclear medicine innovation and development by combining the advantages of all parties. (by Scientific News Dept.)
[Editor: Ruidong Gao]